Literature DB >> 8125513

Superantigen mediated shock: a cytokine release syndrome.

T Miethke1, C Wahl, D Regele, H Gaus, K Heeg, H Wagner.   

Abstract

Treatment of animals with superantigens results in profound immunological changes. A major fraction of all peripheral T cells becomes activated in vivo. Subsequently, successive waves of cytokines are produced with TNF playing a central pathophysiologic role. In addition, if the liver is damaged by an as yet poor defined mechanism the consequences of the cytokine syndrome are life threatening. However, TNF alone is not sufficient to cause death, instead synergizing interactions with cytokines like IL-1, IL-6, and IFN-gamma are probably involved. On the other hand, certain experimental conditions prevent these waves of cytokines and consequently lethal shock. Furthermore, a significant fraction of SA reactive T cells are deleted by programmed cell death 10 to 24 hours after treatment. Thereafter the surviving cells proliferate vigorously until day 2 or 3, followed by a second wave of apoptosis resulting in reduced SA reactive T cell numbers as compared to pretreatment levels. Of course, many aspects of the complicated events are only marginally understood and deserve further investigation.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8125513     DOI: 10.1016/S0171-2985(11)80362-1

Source DB:  PubMed          Journal:  Immunobiology        ISSN: 0171-2985            Impact factor:   3.144


  32 in total

1.  Distinct functions of interferon-gamma for chemokine expression in models of acute lung inflammation.

Authors:  B Neumann; K Emmanuilidis; M Stadler; B Holzmann
Journal:  Immunology       Date:  1998-12       Impact factor: 7.397

2.  Modulation of endotoxin- and enterotoxin-induced cytokine release by in vivo treatment with beta-(1,6)-branched beta-(1,3)-glucan.

Authors:  J Soltys; M T Quinn
Journal:  Infect Immun       Date:  1999-01       Impact factor: 3.441

Review 3.  Evidence for a superantigen in the pathogenesis of tuberculosis.

Authors:  J D Ohmen; R L Modlin
Journal:  Springer Semin Immunopathol       Date:  1996

4.  Genetically engineered superantigens as tolerable antitumor agents.

Authors:  J Hansson; L Ohlsson; R Persson; G Andersson; N G Ilbäck; M J Litton; T Kalland; M Dohlsten
Journal:  Proc Natl Acad Sci U S A       Date:  1997-03-18       Impact factor: 11.205

5.  Role of miRNA in the regulation of inflammatory genes in staphylococcal enterotoxin B-induced acute inflammatory lung injury and mortality.

Authors:  Roshni Rao; Prakash Nagarkatti; Mitzi Nagarkatti
Journal:  Toxicol Sci       Date:  2015-01-05       Impact factor: 4.849

6.  Prevalence of genes encoding pyrogenic toxin superantigens and exfoliative toxins among strains of Staphylococcus aureus isolated from blood and nasal specimens.

Authors:  Karsten Becker; Alexander W Friedrich; Gabriele Lubritz; Maria Weilert; Georg Peters; Christof Von Eiff
Journal:  J Clin Microbiol       Date:  2003-04       Impact factor: 5.948

7.  Clinical role for a superantigen in Yersinia pseudotuberculosis infection.

Authors:  J Abe; M Onimaru; S Matsumoto; S Noma; K Baba; Y Ito; T Kohsaka; T Takeda
Journal:  J Clin Invest       Date:  1997-04-15       Impact factor: 14.808

8.  Opsonic antibodies to the surface M protein of group A streptococci in pooled normal immunoglobulins (IVIG): potential impact on the clinical efficacy of IVIG therapy for severe invasive group A streptococcal infections.

Authors:  H Basma; A Norrby-Teglund; A McGeer; D E Low; O El-Ahmedy; J B Dale; B Schwartz; M Kotb
Journal:  Infect Immun       Date:  1998-05       Impact factor: 3.441

9.  Biological activity of toxic shock syndrome toxin 1 and a site-directed mutant, H135A, in a lipopolysaccharide-potentiated mouse lethality model.

Authors:  B G Stiles; T Krakauer; P F Bonventre
Journal:  Infect Immun       Date:  1995-04       Impact factor: 3.441

10.  IL-2 regulates SEB induced toxic shock syndrome in BALB/c mice.

Authors:  Aslam Ali Khan; Shilpee Priya; Bhaskar Saha
Journal:  PLoS One       Date:  2009-12-29       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.